Breathonix
Breathonix is a Singapore-based NUS spin-off that develops PTR-MS breath analysis systems with proprietary machine learning algorithms for non-invasive disease detection, including COVID-19, diabetes, and lung cancer, serving enterprise and government healthcare clients across Asia.
- Company typePrivate
- Founded2018
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Breathonix does
Breathonix is a Singapore-based deep-tech company founded in 2018 as a spin-off from the National University of Singapore (NUS) through the Graduate Research Innovation Programme (GRIP). The company specializes in breath-based disease detection using Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with proprietary machine learning algorithms to analyze volatile organic compound (VOC) signatures in exhaled breath. Its core products include the BreFence Go COVID-19 Breath Test System, which received Health Sciences Authority (HSA) provisional authorization, and the MetaDR Breath Analyser for diabetes monitoring. The company is also developing applications for lung cancer detection.
The business operates on a B2B model, selling or deploying its breath analysis hardware and consumables to enterprise and government clients. Notable commercial agreements include a USD 20 million deal with Vingroup for 30 machines in Vietnam and an exclusive distribution partnership with MyEG in Malaysia. The company has secured multiple regulatory clearances including HSA, CE Mark, MDA, and FDA registration, along with ISO 13485 certification, enabling cross-border deployment. Revenue mechanics appear to be a combination of equipment sales and ongoing service/consumable contracts, though no recurring revenue figures are disclosed.
Customer concentration is significant, with major contracts tied to government health authorities (Singapore MOH, UAE DHA/MBRU) and large enterprise partners (Vingroup, MyEG). The company maintains a modest headcount of 11-50 employees and has raised approximately USD 300K-400K in total funding through pre-seed grants and a Pre-Series A round targeting USD 5 million. Its competitive position rests on 6 patents, peer-reviewed clinical validation, and an experienced founding team led by Prof T Venkatesan (h-index 110, 6 prior startups).
Breathonix firmographics
Firmographics- Name
- Breathonix
- Legal name
- Breathonix Pte Ltd.
- Website
- https://breathonix.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Breathonix is a Singapore-based NUS spin-off that develops PTR-MS breath analysis systems with proprietary machine learning algorithms for non-invasive disease detection, including COVID-19, diabetes, and lung cancer, serving enterprise and government healthcare clients across Asia.
- Ownership category
- akta.pro rank
Breathonix industry classification
Industry- Product category
- Medical Diagnostics Devices
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH)
- akta.pro secondary industries
- Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC), Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD), Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB)
Keywords
Where Breathonix is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
Breathonix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Breath Test Hardware and Service Provision: One-stop service model providing both proprietary breath test machines and professional on-site manpower. Target pricing of US$20 per test, significantly lower than PCR tests costing ~$200.
- COVID-19 Breath Testing System: Sale of BreFence Go COVID-19 breath test systems with disposable mouthpieces to governments, hospitals, airports, and enterprises for mass screening deployments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Per-test pricing model |
| Other | Multi-year contract | One-stop service model |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
Breathonix product offering
Product offeringCore offering
Breathonix develops proprietary breath analysis systems that use Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with machine learning algorithms to detect Volatile Organic Compounds (VOCs) in exhaled breath. The company manufactures and sells two core products: the BreFence Go COVID-19 Breath Test System for rapid infectious disease screening and the MetaDR Breath Analyser for non-invasive ketone monitoring in diabetes and diabetic ketoacidosis.
Product overview
Breathonix is a deep-tech venture specializing in advanced breath analysis technology for early disease detection. The company offers two core breath analysis products: (1) the BreFence Go COVID-19 Breath Test System, a mass spectrometry-based diagnostic platform that detects VOCs in exhaled breath for COVID-19 screening and received HSA provisional authorization in Singapore, and (2) the MetaDR Breath Analyser, an FDA-registered portable handheld device for breath ketone monitoring for diabetes management and diabetic ketoacidosis detection. Both products use proprietary breath sampling technology and AI-based algorithms to analyze volatile organic compounds, representing a unified platform approach to non-invasive disease detection through breath biomarkers.
Differentiator
Problem solved
Functional benefit
Brands
- BreFence Go: COVID-19 Breath Test System - real-time, non-invasive breath test for qualitative detection of volatile organic compounds (VOCs) indicative of COVID-19 presence.
- MetaDR
Products and services
- BreFence Go COVID-19 Breath Test System A real-time, non-invasive breath test system for qualitative detection of volatile organic compounds (VOCs) in human breath, used by governments, hospitals, airports and large enterprises for mass COVID-19 screening. Uses mass spectrometry combined with machine learning algorithms to generate results in under 60 seconds with 85.7% sensitivity and 97% specificity.
- MetaDR Breath Analyser A portable hand-held FDA-registered breath analyser for rapid, safe and non-invasive breath ketone monitoring, used for home monitoring of diabetes, emergency diagnosis of diabetic ketoacidosis, and non-invasive monitoring of epilepsy. Delivers results in 10 seconds and pairs with a companion phone app for data storage and health management.
Quantifiable outcome
- Results delivered in under 60 seconds from breath sampling
- +4 more outcomes
Companies that use Breathonix
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Breathonix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature5 records
Breathonix partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered strategic, core, minor and foundational.
- University of OklahomastrategicCollaborative study published in Open Access Government focused on non-invasive VOC breathomics for pandemic preparedness. Supported by NSF funding, combining OU's clinical research and AI/ML expertise with Breathonix's breath analysis technology.
- ZühlkestrategicStrategic technology partnership for digital innovation and data-driven deployment efforts. Zühlke provided solution architecture support and identified opportunities for scaling digital and innovation capabilities, including data security considerations.
- AccredifycoreIntegration of BreFence Go breath test with Accredify's digital verifiable COVID-19 test result issuance system. Results will be internationally recognized in 82 countries and 292 airlines, compliant with Singapore's HealthCerts schema.
- VingroupcoreVietnamese conglomerate deal valued at over 460 billion VND (20 million USD) comprising 30 testing machines and disposable mouthpieces capable of collecting 2 million samples. System presented to Vietnam Ministry of Health.
- MyEG ServicescoreMalaysia-based government services provider appointed as exclusive distribution partner for commercial sale, marketing, and deployment of Breathonix COVID-19 breath testing systems in Malaysia. MyEG to apply for regulatory approvals and certifications for commercial availability.
- Dubai Health Authority (DHA)coreJoint clinical trial at DHA's Nadd Al Hamar primary health care centre for 2,500 patients to assess accuracy of rapid COVID-19 breath test. Trial part of UAE's efforts to foster medical research and innovation.
- Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU)coreJoint clinical trial collaboration for rapid COVID-19 breath test accuracy assessment. MBRU served as catalyst for medical research in the region with focus on COVID-19 studies and technology transfer.
- Emirates AirlineminorEmirates provided world-class services and sponsored expedited transportation of Breathonix's breath test system from Singapore to Dubai to support clinical trial. Part of Dubai's efforts to implement innovative testing approaches.
- National University of Singapore (NUS)foundationalSpin-off company from NUS through Graduate Research Innovation Programme (GRIP). Technology originated from 6+ years of research at NUS Nanoscience and Nanotechnology Institute. Supported by NUS in regulatory approvals and clinical trials.
- Singapore Ministry of HealthcoreWorking with MOH for deployment trial at land checkpoint (Tuas Checkpoint) where incoming travelers undergo screening with BreFence Go COVID-19 breath test alongside antigen rapid tests.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Breathonix competitors and assessment
Company assessmentBroad incumbents
- MGC Diagnostics (now part of CAIRE): MGC Diagnostics is an established provider of pulmonary function testing equipment and related software. It is comparable to Breathonix in the pulmonary function testing (PFT) category, although focused on traditional lab-based PFT hardware rather than mass-spectrometry VOC detection.
- Vyaire Medical: Vyaire Medical is a large respiratory diagnostics company supplying pulmonary function testing and spirometry equipment globally. It competes with Breathonix's breath-based diagnostic equipment in hospital and clinical lab settings, though with broader product lines.
- Pulmonx: Pulmonx is a publicly traded lung diagnostics and interventional pulmonology company. While more procedurally focused, it addresses the same end customer (pulmonologists, lung cancer programs) and competes for budget allocation in the respiratory diagnostic pathway.
- Cepheid (a Danaher company): Cepheid's GeneXpert PCR systems are the dominant rapid molecular diagnostic platform that Breathonix positions BreFence Go against. While not a breath company, it is the incumbent standard Breathonix's cost/speed proposition targets in the COVID-19 and infectious disease screening market.
Direct peers
- Spirosure: Spirosure (formerly Advanced Breath Diagnostics) develops breath-based diagnostic devices, particularly for respiratory conditions such as asthma. It overlaps with Breathonix in deploying non-invasive breath analysis hardware for clinical screening.
- Menssana Research: Menssana Research develops breath tests for a range of diseases using mass-spectrometry-based VOC detection. It is directly comparable to Breathonix in terms of technology platform and target applications (infectious disease, oncology, metabolic monitoring).
- Owlstone Medical: Owlstone Medical is a UK-based breath biopsy company that uses VOC analysis for early disease detection, including lung cancer. It is the closest direct peer to Breathonix, operating in the same breath-based diagnostic category with overlapping disease indications and a similar platform-based, biomarker-driven approach.
Emerging players
- CMI Health: CMI Health manufactures handheld respiratory monitoring devices, including breath-based analyzers. It is comparable to Breathonix's MetaDR product line in portable breath analysis, though with a broader consumer/wellness positioning.
- AerNos: AerNos builds nano-sensor-based breath analysis devices for health and environmental monitoring. While more sensor-focused than Breathonix's mass spectrometry approach, it competes in the same breath-based diagnostic category, particularly for point-of-care and consumer health use cases.
- Resmon (used to be: Resmed SaaS / Resmon Med): Resmon offers AI-based lung function/respiratory analysis using cough and breath acoustics. It represents an emerging digital-health approach that could partially substitute for or complement Breathonix's hardware-based breath diagnostic pathway in screening settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Breathonix social profiles
Digital presenceBreathonix compliance and trust
Trust signalCompliance5 records
Breathonix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Breathonix leadership team
Management profileNumber of profiles
Profiles8 records
Breathonix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Breathonix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Breathonix
What does Breathonix do?
Breathonix develops proprietary breath analysis systems that use Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with machine learning algorithms to detect Volatile Organic Compounds (VOCs) in exhaled breath. The company manufactures and sells two core products: the BreFence Go COVID-19 Breath Test System for rapid infectious disease screening and the MetaDR Breath Analyser for non-invasive ketone monitoring in diabetes and diabetic ketoacidosis.
Is Breathonix a public or private company?
Breathonix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Breathonix founded?
Breathonix was founded in 2018. It employs 11 to 50 people.
Where is Breathonix based?
Breathonix is headquartered in Singapore, Singapore, in the Asia region.
How does Breathonix make money?
Two revenue lines are on record. Breath Test Hardware and Service Provision is the primary driver. The others are COVID-19 Breath Testing System.
Who are Breathonix's main competitors?
Broad incumbents on record are MGC Diagnostics (now part of CAIRE), Vyaire Medical, Pulmonx and Cepheid (a Danaher company). Direct peers are Spirosure, Menssana Research and Owlstone Medical. Emerging players are CMI Health, AerNos and Resmon (used to be: Resmed SaaS / Resmon Med).
Does Breathonix have an API?
No public API is recorded for Breathonix.
What industry is Breathonix in?
Breathonix's product category is Medical Diagnostics Devices. Its primary akta.pro industry code is HLAHAGAH, Pulmonary Function Testing (PFT) & Spirometry Equipment, with a secondary code of HLAKANAC, Pulmonary Function Testing (PFT) & Respiratory Diagnostics. Its NAICS code is 334516 and its SIC code is 3826.